Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients

Nov 4, 2024Scientific reports

Link between blood uric acid levels and death from any cause or heart problems in people with heart disease

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a cohort of 3,977 patients with cardiovascular disease, 34.2% died during a median follow-up of 68 months.

is associated with an increased risk of (ACM) and (CVM) in patients with cardiovascular disease.
Participants in the highest quartile of serum uric acid levels had a hazard ratio of 1.38 for ACM and 1.39 for CVM.
A nonlinear relationship exists between serum uric acid levels and mortality, particularly in men and those with chronic kidney disease.
Thresholds for the association between serum uric acid and ACM and CVM were identified at levels of 5.49 and 5.64, respectively.
Time-dependent analyses indicated moderate predictive accuracy for survival outcomes at 1, 3, 5, and 10 years.

AI simplified

The relationship between (SUA) and mortality in patients with cardiovascular disease (CVD) remains controversial. We aimed to explore the relationship between SUA and (ACM) and (CVM) in adult patients with CVD. This cohort study included 3977 patients with CVD from the National Health and Nutrition Examination Survey (2005-2018). Death outcomes were determined by linking National Death Index (NDI) records through December 31, 2019. We explored the association of SUA with mortality using weighted Cox proportional hazards regression models, subgroup analysis, Kaplan-Meier survival curves, weighted restricted cubic spline (RCS) models, and weighted threshold effect analysis among patients with CVD. During a median follow-up of 68 months (interquartile range, 34-110 months), 1,360 (34.2%) of the 3,977 patients with cardiovascular disease died, of which 536 (13.5%) died of cardiovascular deaths and 824 (20.7%) died of non-cardiovascular deaths. In a multivariable-adjusted model (Model 3), the risk of ACM (HR 1.38, 95% CI 1.16-1.64) and the risk of CVM (HR 1.39, 95% CI 1.04-1.86) for participants in the SUA Q4 group were significantly higher. In patients with CVD, RCS regression analysis revealed a nonlinear association (p < 0.001 for all nonlinearities) between SUA, ACM, and CVM in the overall population and in men. Subgroup analysis showed a nonlinear association between ACM and CVM with SUA in patients with CVD combined with chronic kidney disease (CKD), with thresholds of 5.49 and 5.64, respectively. Time-dependent ROC curves indicated areas under the curve of 0.61, 0.60, 0.58, and 0.55 for 1-, 3-, 5-, and 10-year survival for ACM and 0.69, 0.61, 0.59, and 0.56 for CVM, respectively. We demonstrate that SUA is an independent prognostic factor for the risk of ACM and CVM in patients with CVD, supporting a U-shaped association between SUA and mortality, with thresholds of 5.49 and 5.64, respectively. In patients with CVD combined with CKD, the association of the ACM and the CVM with SUA remains nonlinear.

Key numbers

1.38

Increase in Risk

Hazard Ratio for in Q4 group vs. Q1 group

1.39

Increase in Risk

Hazard Ratio for in Q4 group vs. Q1 group

34.2%

Percentage of Patients Who Died

Proportion of deaths during a median follow-up of 68 months

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief